BCL2 and type 1 diabetes mellitus: A recent study has indicated that in T1D, a subset of β cells acquires a senescence-associated secretory phenotype (SASP) associated with increased BCL2 expression.501 Treatment with senolytic BH3-mimetics (see below) may eliminate these senescent cells and prevent immune-mediated β cell destruction, indicating a new treatment strategy for T1D.